Issue link: http://deals.uberflip.com/i/1534864
Clinical Research Organization & Biospecimen Supplier Providing Management & Execution of Clinical Trials #68785 Sign NDA ► Location: California 2025 Est. Revenue $15,700,000 2025 Est. EBITDA $7,328,000 DISCLAIMER: All information contained in this document has been provided by the subject company to Generational Equity and while believed to be correct has not been verified. Accordingly, Generational Equity makes no representations or warranties as to the accuracy and truthfulness of such information. The recipient hereof acknowledges that Generational Equity shall not be liable for any loss or injury suffered by said recipient in any way connected to the delivery by Generational Equity of this document. At all times Generational Equity and its affiliate network members is an agent for the seller and not for the buyer. Generational Equity's fees are paid by the seller. Fred Zweifel Lori Galloway Senior Managing Director Executive Managing Director Email: fzweifel@generational.com lgalloway@generational.com Office: 972-232-1109 949-466-0433 Generational Equity, LLC 3400 N. Central Expressway, Ste. 100 Richardson, TX 75080 Fax: 972-392-8564 BUSINESS HIGHLIGHTS This outstanding acquisition opportunity is for a privately-owned, full -service Clinical Research Organization (CRO) and biospecimen broker specializing in the collection and supply of biospecimens for the biotech, pharmaceutical, and clinical research industries. The Company has a large number of collection sites across the U.S. and internationally. The Company offers a full range of CRO services, including site management, data collection and feedback, and help with FDA approval for Clinical Trials Phases 1-4. * Only considering strategic buyers & PEGs with related holdings INVESTMENT BANK OF THE YEAR 2017 - 2018 - 2022 INVESTMENT APPEAL • Superior Name & Reputation — The Company enjoys a long-standing reputation for the quality of its products and services, expertise, dependability, and superior customer support. As a result, the majority of its business is from repeat business and referrals. • Strong Management Team — The Company's management team has a tremendous amount of experience in the industry. The management team is focused on providing quality, timely, and cost-effective products, coupled with proactive and responsive customer service. • Numerous National & International Collection Sites — The Company has a large number of collection sites in geographically diverse locations, both nationally and internationally. The collection sites cover a wide range of clinical conditions including infectious disease, respiratory, cardiac, and women's health, to name a few. • Recession-Resistant Industry — Management indicates that demand for the Company's products and services are inelastic. Regardless of economic conditions, the demand for its products and services remains consistent. • Strong Historical Sales Growth — The Historical sales have grown from $11.381mm in 2022 to $13.06mm in 2024, representing a compound annual growth rate of 7.1%. Sales have grown consistently year over year in the historical period.